Diabetes and percutaneous coronary revascularization in the drug-eluting stent era.
Diabetes mellitus has reached epidemic proportions and is associated with decreased event-free survival following coronary revascularization. Although the historical complication rates for diabetic patients following percutaneous coronary intervention have been less than acceptable, the emerging drug-eluting stent technology when coupled with an aggressive adjunctive pharmacological regimen will improve the complication rates following percutaneous revascularization for this high-risk group of patients. This review will focus on the historical data associated with revascularization, percutaneous and surgical, and diabetes mellitus and will highlight the emerging data of drug-eluting stents and adjunctive pharmacology.
Safley
David M
DM
University of Missouri, Kansas City, Missouri, USA.
Marso
Steven P
SP
D001026:Coronary Artery Bypass / Q000379:methods*; D003324:Coronary Artery Disease / Q000150:complications* / Q000628:therapy*; D048909:Diabetes Complications / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans